A phase 3 study assessing the use pregabalin as adjunctive therapy for epilepsy patients 5 to 65 years of age with primary generalized tonic-clonic (PGTC) seizures did not meet its primary endpoint to ... Nasdaq: UCB's VIMPAT® (lacosamide) CV now approved by FDA for primary generalized tonic-clonic seizures and expanded pediatric use for people living with epilepsy UCB's VIMPAT® (lacosamide) CV now approved by FDA for primary generalized tonic-clonic seizures and expanded pediatric use for people living with epilepsy Yahoo: Pediatrics in Brevard: Here's what to know about epilepsy, what to do if someone has seizure Add Yahoo as a preferred source to see more of our stories on Google. More than 3.4 million people in the United States have epilepsy, so it is a relatively common diagnosis.

Understanding the Context

In fact, it is the fourth ... Pediatrics in Brevard: Here's what to know about epilepsy, what to do if someone has seizure Monthly Prescribing Reference: Phase 3 Study Results Announced for Pregabalin in Primary Generalized Tonic-Clonic Seizures Phase 3 Study Results Announced for Pregabalin in Primary Generalized Tonic-Clonic Seizures